CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ...
Interim data from Phase 1 with single and multiple ascending doses show no safety signals and a generally favorable tolerability profile of AGMB-447 in healthy participants --- ...
ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in ...
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) The purpose of this ...
MONTPELLIER, France--(BUSINESS WIRE)--An original presentation describing pharmacokinetic characteristics of an investigational long-acting subcutaneous formulation of olanzapine (mdc-TJK or TEV-44749 ...
Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: ...
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory ...
Poherdy is supplied as a 420mg/14mL solution in a single-dose vial. The approval was based on a comprehensive review of clinical data, which included a pharmacokinetic phase 1 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback